Close
provider
Search result for "Solr search content"
Search Result for ""
provider
Georgios Fotopoulos, MD, PhD, FSMB Thoracic Oncology, Experimental Therapeutics
Story
Mays Cancer Center partners with American Cancer Society to increase lung cancer screenings in South Texas
Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is partnering with the American Cancer Society to spread awareness and encourage more at-risk South Texans to screen for lung cancer.
provider
Neil Newman, MD Radiation Oncology, Thoracic Radiation Oncology
Story
Mays Cancer Center at UT Health San Antonio identifies possible markers for early metastatic lung cancer
Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment. The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of […]
Story
Mays Cancer Center Partners with Nation’s Top Cancer Organizations to Endorse Initiative to Increase Lung Cancer Screening in the United States
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (Nov. 1, 2022) – Lung cancer is the leading cause of cancer death in the United States, accounting for almost 25% of […]
provider
William Kelly, MD Neuro-Oncology, Thoracic Oncology
Screenings & Diagnosis
Screening & Diagnosis
Clinical Trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nabpaclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).